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Drosophila Enabled (Ena) was initially identified as a dominant genetic suppressor of 
mutations in the Abelson tyrosine kinase and, more recently, as a member of the 
Ena/human vasodilator-stimulated phosphoprotein (VASP) family of proteins. We have 
used genetic, biochemical, and cell biological approaches to demonstrate the functional 
relationship between Ena and human VASP. In addition, we have defined the roles of 
Ena domains identified as essential for its activity in vivo. We have demonstrated that 
VASP rescues the embryonic lethality associated with loss of Ena function in Drosophila 
and have shown that Ena, like VASP, is associated with actin filaments and focal 
adhesions when expressed in cultured cells. To define sequences that are central to Ena 
function, we have characterized the molecular lesions present in two lethal ena mutant 
alleles that affected the Ena/VASP homology domain 1 (EVH1) and EVH2. A missense 
mutation that resulted in an amino acid substitution in the EVH1 domain eliminated in 
vitro binding of Ena to the cytoskeletal protein zyxin, a previously reported binding 
partner of VASP. A nonsense mutation that resulted in a C-terminally truncated Ena 
protein lacking the EVH2 domain failed to form multimeric complexes and exhibited 
reduced binding to zyxin and the Abelson Src homology 3 domain. Our analysis 
demonstrates that Ena and VASP are functionally homologous and defines the conserved 
EVH1 and EVH2 domains as central to the physiological activity of Ena.
IN T R O D U C T IO N
Changes in cytoskeleton assembly and cell adhesion in 
response to extracellular cues are critical in regulating 
diverse cellular functions (Damsky, 1993; Rubinfeld et 
al., 1993; Su et al., 1993; Montell, 1994). Translation of 
these extracellular signals into cytoskeletal changes 
are mediated by signal transduction pathways
+ Corresponding author.
(Tanaka and Sabry, 1995). In Drosophila, the Abelson 
(Abl) tyrosine kinase and its substrate Enabled (Ena) 
are thought to play a role in regulating cytoskeletal 
changes during axonogenesis in the CNS of the devel­
oping embryo (Gertler et al., 1989, 1995; Bennett and 
Hoffmann, 1992; Hill et al., 1995). This hypothesis has 
been bolstered by the recent identification of Drosoph­
ila Ena as a member of the cytoskeletal-associated 
Ena/human vasodilator-stimulated phosphoprotein 
(VASP) family of proteins (Gertler et al., 1996). Mem-
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bers of this family in addition to Drosophila Ena in­
clude VASP, murine Ena (Mena), and murine Ena/ 
VASP-like (EVL) protein. Mena and VASP have been 
localized to the actin cytoskeleton and are in vitro 
ligands for the focal adhesion-associated protein zyxin 
and the actin-binding protein profilin (Reinhard et al., 
1992, 1995a; Haffner et al., 1995; Gertler et al., 1996). 
Drosophila Ena also binds profilin in vitro (our unpub­
lished results). Mena and VASP interact with Act A, a 
protein from Listeria monocytogenes required for the 
recruitment of host actin filaments around the intra­
cellular bacteria, and VASP and Mena may serve as 
links between ActA and profilin. Consequently, these 
proteins may enhance Act A-mediated F-actin recruit­
ment that is used as a means of intracellular move­
ment by the bacteria (Chakraborty et al., 1995; Pistor et 
al., 1995; Pollard, 1995; Gertler et al., 1996). Additional 
support for a direct role in cytoskeleton assembly 
comes from the observation that overexpression of 
neuronally enriched forms of Mena in cultured cells 
results in actin-rich membrane projections (Gertler et 
al., 1996) and that targeting of the Mena- and VASP- 
binding protein zyxin to the plasma membrane causes 
the elaboration of actin-rich projections (Golsteyn et 
al, 1997).
The Ena/VASP family of proteins is characterized 
by a common overall structural domain organization 
consisting of conserved N- and C-terminal domains 
separated by a less-conserved central proline-rich re­
gion (Gertler et al., 1996). This N-terminal 113-amino- 
acid domain, or the Ena/VASP homology domain 1 
(EVH1), is 58% identical between Drosophila Ena and 
human VASP. The EVH1 domain mediates VASP and 
Mena binding to the focal adhesion-associated protein 
zyxin as well as Listeria Act A  (Gertler et al., 1996). The 
EVH1 domain is also similar to the WP1 domain 
found in Wiskott-Aldrich syndrome protein (Symons 
et al., 1996). Wiskott-Aldrich syndrome is character­
ized by cytoskeletal abnormalities in T cells and plate­
lets (Derry et al., 1995; Kolluri et al., 1995; Kwan et al., 
1995; Villa et al., 1995; Wengler et al., 1995; Zhu et al., 
1995). The central proline-rich regions of the Ena, 
Mena, and VASP proteins, which vary greatly in 
length, are important for binding to both Src homol­
ogy 3 (SH3) domains and the actin-binding protein 
profilin (Gertler et al., 1995, 1996; Reinhard et al., 
1995a) (our unpublished results). The C-terminal 35 
amino acids of these proteins, or the EVH2 domain, is 
31% identical between Drosophila Ena and human 
VASP and consists of a series of conserved charged 
repeats with a spacing predicted to form an extended 
highly charged a  helix (Haffner et al., 1995). Homology 
to this region is also seen in human expressed se­
quence tag r74407 and the mouse cDNA NDPP-1 (Sa- 
zuka et al., 1992). Several functions have been pro­
posed for the EVH2 domain, including subcellular 
localization and mediation of multimer formation
(Haffner et al., 1995; Gertler et al., 1996), although 
conclusive evidence for these proposed functions has 
not been reported.
In addition to a role in cytoskeleton assembly, Ena/ 
VASP proteins are constituents of signal transduction 
pathways. Ena has been linked genetically to the Abl 
tyrosine kinase signaling pathway by identification of 
ena mutations that act as dominant genetic suppres­
sors of a loss of Abl tyrosine kinase function (Gertler et 
al., 1990). Heterozygous loss of function mutations in 
ena rescue the lethality and defects in axonal architec­
ture in embryos with mutations in Abl and other 
components of Abl-mediated signaling (Gertler et al., 
1989, 1993; Hill et al. , 1995). Drosophila that lack Ena 
function die during embryogenesis and also display 
defects in the axonal architecture of the nervous sys­
tem. These include a reduction in the integrity of axon 
bundles and some axon misrouting consistent with a 
role for Ena in regulating the cytoskeleton (Gertler et 
al., 1990 1995). Ena is a specific substrate for Abl and 
also specifically interacts with the Abl SH3 domain 
(Gertler et al., 1995).
Ena's homology to a family of proteins clearly im­
plicated in cytoskeletal dynamics led us to investigate 
possible conserved functions between Ena and VASP. 
We report that VASP can partially substitute for Ena 
function in Drosophila. In addition, we show that Ena 
and VASP are colocalized at focal adhesions and with 
actin filaments. We have characterized two lethal mu­
tations and show that they result in defects in the 
EVH1 and EVH2 domains of Drosophila Ena. Further­
more, we demonstrate that these mutations disrupt 
conserved functions of Ena/VASP proteins, namely in 
vitro zyxin binding and multimerization. We further 
demonstrate that Ena and VASP are colocalized to 
focal adhesions with zyxin, providing indirect evi­
dence that these proteins may interact in the intact 
cell. The evidence for conservation of function be­
tween Drosophila Ena and human VASP suggests that 
Ena may provide a regulated link between Abl-medi- 
ated signal transduction and cytoskeletal dynamics in 
the developing Drosophila CNS.
M A T E R IA L S  A N D  M E T H O D S
Transfections and Western B lot Analysis
DNA encoding six histidine residues, the FLAG tag, or the hema- 
glutinin (Ha) tag was added to the 3' end of the coding sequence of 
the ena cDNA by PCR. Drosophila S2 cells were transiently trans­
fected with VASP, Abl, Ena, or tagged Ena cDNAs in the pPac-PL 
expression vector. Cells were harvested after 60 h and lysed in 
immunoprecipitation buffer (0.5% Triton X-100, 50 mM Tris, pH 8.0, 
150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 1 mM Pefabloc (Boehr- 
inger Mannheim, Indianapolis, IN), 1 /xg/ml each pepstatin, leu- 
peptin, and aprotinin) or His buffer (0.5% Triton X-100, 20 mM 
NaPO4, pH 7.8, 500 mM NaCl, 1 mM Na3VO4, 1 mM Pefabloc, 1 
g/ml each pepstatin, leupeptin, and aprotinin). After lysis, cell 
debris was pelleted at 12,000 g for 20 min. Immunoprecipitations 
were carried out as previously described using anti-Ena (Gertler et
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al., 1995), anti-VASP (Halbrugge et al., 1990), anti-FLAG M2, or 
anti-Ha 12CA5 antibodies. His-tagged Ena was purified by incubat­
ing lysates with 35 /xl of Ni-nitrilotriacetic acid (NTA)-agarose (Qia- 
gen, Chatsworth, CA) for 1 h at 4°C. Nonspecifically bound proteins 
were eluted with His buffer plus 100 mM imidazole. Proteins were 
resolved on 7.5% SDS-polyacrylamide gels, transferred to a polyvi- 
nylidene difluoride membrane, and blotted with anti-Ena, anti- 
VASP, anti-Ha 12CA5, anti-FLAG M2 (Molecular Probes, Eugene, 
OR), or anti-phosphotyrosine mAb 4G10 (Upstate Biotechnology, 
Lake Placid, NY) antibodies.
Sequencing o f Mutant ena Alleles
Total RNA was prepared from Drosophila pupae carrying heterozy­
gous wild-type and mutant ena210 or ena23 alleles using Tri reagent 
(Molecular Research Center, Cincinnati, OH). Reverse transcription 
PCR was carried out by priming first-strand synthesis with an Ena 
oligonucleotide that hybridizes to the last 20 nucleotides in the Ena 
open reading frame. The Ena coding sequences were subsequently 
amplified with three sets of primers that amplified the 5 600 nu­
cleotides, middle 600 nucleotides, and 3 700 nucleotides, respec­
tively. PCR products were subcloned into the TA cloning vector 
system (Invitrogen, San Diego, CA), and at least eight independent 
subcloned PCR products were sequenced for each of the PCR prod­
ucts. As expected, half of the subcloned PCR products carried the 
ena210 or ena23 mutation, and half were wild type.
Site-directed Mutagenesis
DNA was purified by standard techniques (Maniatis et al., 1982). 
Site-directed mutagenesis of Ena was performed by the method of 
Deng and Nickoloff (1992). Oligonucleotides containing single-base 
changes that changed Ala-98 to Val and Lys-636 to a stop codon 
were incorporated into a full-length Ena cDNA. The entire mu- 
tagenized DNA fragment was sequenced to confirm the absence of 
any other mutations that may have been inadvertently generated 
during the procedure.
Preparation and Purification o f Recombinant Ena 
and Fusion Proteins and In Vitro Synthesis o f 
Proteins
The His-tagged Ena construct was subcloned into the baculovirus 
vector pVL1393 (Invitrogen). Spodoptera frugiperda SF9 cells were 
cotransfected with 2.5 ^g of pVL1393-Ena plus 200 ng of Baculogold 
viral DNA (Pharmingen, San Diego, CA) to recover recombinant 
virus. High-titer virus stocks were generated and used to infect 2 
108 SF9 cells. At 48 h after infection, cells were harvested and lysed 
in 20 ml of 0.5% Triton X-100, 20 mM NaPO4 (pH 7.8), 500 mM 
NaCl, 1 mM Na3VO4, 1 mM Pefabloc, and 1 /Ag/ml each pepstatin, 
leupeptin, and aprotinin. After lysis, cell debris was pelleted at
12,000 g for 20 min, and the lysate was incubated with 2 ml of 
NTA-agarose (Qiagen) for 1 h at 4°C. Nonspecifically bound pro­
teins were eluted with His buffer plus 100 mM imidazole and Ena 
protein was eluted with 20 mM piperazine-N,N -bis(2-ethanesul- 
fonic acid), 500 mM NaCl, and 300 mM imidazole and stored at 4°C.
A PCR fragment encoding the Drosophila Abl SH3 domain (amino 
acids 82-325) was subcloned into the BamHI site of the pGEX2TK 
vector (Pharmacia, Piscataway, NJ). The chicken zyxin translated 
region encoding amino acids 1-542 was subcloned into the EcoRI 
site of a modified pGEX expression vector. The chicken zyxin LIM 
domain (amino acids 349-542) and the chicken zyxin proline-rich 
region (amino acids 1-348) were also subcloned into the EcoRI site 
of a modified pGEX vector (Schmeichel and Beckerle, 1994). GST 
fusion proteins were expressed in Escherichia coli DH5 and pre­
pared as previously described (Gertler et al., 1995). Ena protein and 
Ena A97V mutant protein were produced in vitro using the Single 
Tube Protein System (Novagen, Madison, WI) after subcloning into
the pCITE vectors. All proteins were quantified by Coomassie blue 
staining or Western blot.
Solution- and Filter-binding Assays
For solution-binding assays, transfected S2 cell lysates were incu­
bated with equivalent amounts of GST-SH3 or GST-Zyxin fusion 
proteins immobilized on glutathione-Sepharose (Pharmacia) for 1 h 
at 4°C. Beads were washed once with immunoprecipitation buffer 
and boiled in SDS sample buffer. Bound proteins were analyzed by 
SDS-PAGE, followed by Western blotting with anti-Ena or anti- 
VASP antibodies. Ena and VASP overlays were carried out essen­
tially as previously described (Reinhard et al., 1995a). Fifty micro­
grams of total protein from human platelets and 100 ng of purified 
porcine platelet zyxin were separated by SDS-PAGE and transferred 
to nitrocellulose. The blot was overlaid with 1 /Ag/ml Ena purified 
from baculovirus-infected cells, and bound Ena was detected by the 
anti-Ena antibody followed by 125I-protein A.
Yeast Two-Hybrid System Screen
A cDNA encoding the C-terminal 243 amino acids of Ena was fused 
to the sequence encoding the GAL4 DNA binding domain in the 
pAS1-CYH2 vector to create pAS-EnaC. The yeast strain Saccharo- 
myces cerevisiae Y190, which contains the reporter genes HIS3 and 
LacZ, was cotransformed with pAS-EnaC and the Drosophila larval 
library pAct (a gift of Dr. Stephen J. Ellidge, Baylor College of 
Medicine, Houston, TX) in which cDNAs are fused to the sequence 
encoding the GAL4 activation domain. Transformants (2.05 X 107) 
were screened for activation of the reporter genes by spreading the 
cells on medium lacking histidine but supplemented with 30 mM 
3-aminotriazole. Colonies that grew in the absence of histidine 
appeared within 7 d after plating and were assayed for -galacto- 
sidase production by a membrane transfer assay. Plasmid DNA 
from the positive clones was isolated and sequenced.
Genetic Stocks and Germ Line Transformation
Drosophila stocks containing ena point mutations and chromosomal 
deletions removing the ena gene have been previously described 
(Gertler et al., 1990, 1995). Flies were cultured on a Drosophila corn- 
meal-yeast extract medium. To construct the transposons used in 
this study, Ena or VASP coding sequences were subcloned into the 
pUAST vector, which contains a minimal promoter preceded by five 
GAL4 binding sites (Brand and Perrimon, 1993). The plasmid DNA 
was injected into white mutant Drosophila embryos, and P element 
transposase was supplied by coinjection of plasmid pPi25.7wc. 
Transformants were identified by pigmentation in the eyes pro­
vided by the white gene in the transposon, and the chromosomal 
location of the transposons was determined genetically. Stocks were 
generated containing both the transgene and heterozygous enaGC5 
mutations.
ena Mutant Rescue Crosses
Chromosomes containing inversions that eliminate the ena gene 
product (enaGC1 and enaGC5) were used in this analysis (Gertler et 
al., 1990, 1995). Ubiquitous expression of the Ena transgenes was 
driven by the GAL4-e22c enhancer trap (generously provided by N. 
Perrimon, Harvard University, Boston, MA). For rescue experi­
ments, enaGC5/Cyo, UAS-Ena, or UAS-VASP virgin females were 
crossed with enaGC1, GAL4-e22c/Cyo males. Progeny were scored 
for the presence of rescued Cy+ enaGC1/enaGC5 flies. Animals 
containing two ena mutant chromosomes were identified as Cy . 
For each cross, the percentage of adult survival was calculated by 
dividing the number of Cy adult flies recovered by the expected 
number of Cy animals. The expected number of Cy animals was 
assumed to be equal to one-half the number of CyO siblings scored. 
The entire progeny were scored from each cross. Rescue with the 
other transgenes was normalized with respect to the rescue seen
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with the wild-type Ena transposon. The values presented are aver­
ages from two or three independent crosses. The absolute amount of 
rescue seen with the Ena transposons varies from cross to cross 
depending on temperature and how crowded the crosses were.
Immunofluorescence Microscopy o f Transfected Cells
Ptk2 cells (CCL56; American Type Culture Collection, Manassas, 
VA) were grown on coverslips in MEM (Life Technologies, Gaith­
ersburg, MD) supplemented with 1% glutamine, 1% nonessential 
amino acids, and 10% FCS. Cells were transfected by the calcium 
phosphate method with pCMV/Ena which consists of the Ena 
cDNA in the pRc/cytomegalovirus (CMV) expression vector (In- 
vitrogen), or pVSV-VASP which consists of human VASP N-termi- 
nally tagged with an epitope of VSV glycoprotein G in the expres­
sion vector pcDNA3 (Invitrogen). Sixteen hours after addition of the 
precipitate, the cells were washed once in PBS, and fresh medium 
was added. Human fibroblasts were grown on coverslips in DMEM 
(Life Technologies)/10%. Cells were transfected by Fugene 6 trans­
fection reagent (Boehringer Mannheim, Indianapolis, IN) with 
pCMV/Ena or the respective constructs into which the Ena23 or 
Ena210 mutations had been introduced.
After 42-53 h, cells were washed with PBS, fixed in 3.7% formal­
dehyde, permeabilized by 0.2% Triton X-100, and incubated with 
rabbit antiserum raised against amino acids 55-235 of Ena (diluted 
1:6 in PBS, 11 /xg/ml) and, for the detection of VSV-G-tagged VASP, 
with mAb P5D4 (Sigma, St. Louis, MO), diluted 1:5000 in PBS. Zyxin 
was detected with the mAb 164D4 raised against human zyxin. In 
PtK2 cells, primary antibodies were detected by TRITC-labeled 
donkey anti-rabbit antibodies (Ena staining) and DTAF-labeled goat 
anti-mouse antibodies (Dianova, Hamburg, Germany). Actin was 
detected with fluorescein-labelled phalloidin (Molecular Probes, Eu­
gene, OR). In human fibroblasts, primary antibodies were detected 
by Oregon Green-labeled goat anti-rabbit antibodies (Ena staining) 
and Cy3-labeled donkey anti-mouse antibodies (zyxin staining). 
The specimens were examined with a Leitz (Wetzlar, Germany) 
Aristoplan microscope equipped with epifluorescence. Photographs 
were taken with Kodak Ektachrome Elite 400 film (Eastman Kodak, 
Rochester, NY).
R E SU LT S
VASP Can Functionally Substitute fo r  a Complete 
Loss o f Ena Protein in Drosophila 
Ena and VASP share sequence identity in two regions 
of the protein thought to be important for function 
(Figure 1A). We wondered whether these similarities 
could be sufficient to permit VASP to partially com­
pensate for a lack of Ena protein during Drosophila 
development. To test this, we generated stable trans­
genic Drosophila expressing human VASP or Drosoph­
ila Ena. Five VASP and three Ena transgenic lines that 
were independently derived were tested for their abil­
ity to rescue the lethality of ena null mutants. When 
expressed ubiquitously via the U A S/G A L4 binary ex­
pression system (Brand and Perrimon, 1993), VASP 
partially rescued ena mutant lethality, allowing 25­
85% of the ena mutant progeny to survive to adult­
hood compared with 79- 100% rescue by the Ena 
transgene (Table 1). As expected, no ena mutant flies 
from these crosses eclosed in the absence of expression 
of an Ena or VASP transgene. All the flies rescued 
with the VASP transgene were visibly normal and had 
comparable fertility and survival 4 wk after eclosion to
flies that were rescued with a Drosophila Ena trans­
gene. The range in rescue seen with the different trans­
genes is likely due to differences in expression levels 
or patterns as a result of the different insertion sites of 
the transgenes. This result suggests that Drosophila 
Ena and human VASP have overlapping in vivo func­
tions and affect similar cellular processes.
Ena and VASP Are Colocalized to Focal Adhesions 
and Actin Stress Fibers
VASP is localized to focal adhesions, stress fibers, and 
cell-cell contacts (Reinhard et al., 1992). The Ena pro­
tein is localized to the axonal tracts of the developing 
Drosophila embryonic CNS (Gertler et al., 1995), but the 
small size of these cells makes higher-resolution local­
ization difficult. Because Ena and VASP have some 
conserved function in vivo, we compared their sub- 
cellular distribution when expressed in mammalian 
cells. Both Ena and VASP were detected at actin fila­
ments and focal adhesion contacts. Coexpression of 
Ena and VASP resulted in an essentially identical pat­
tern of expression (Figure 2). These results indicate 
that both proteins have domains sufficient to permit 
binding in vivo to proteins in the actin cytoskeleton 
and focal adhesions.
Identification o f Lethal Mutations in the EVH1 and 
EVH2 Domains o f Drosophila Enabled 
Mutant ena alleles that were generated by mutagenesis 
with ethyl-nitroso-urea during the genetic screen that 
identified ena as a dominant genetic suppressor of abl 
mutations result in 100% lethality when expressed 
over an ena deficiency (Table 2). Because ethyl-nitroso- 
urea normally introduces single-base changes, we 
tested for the expression of Ena protein from these 
mutant alleles by Western blot analysis of single em­
bryos from stocks of flies heterozygous for the ena 
mutation of interest. A  chromosomal inversion 
(enaGC8) known to be null for Ena protein was used as 
a control. Because the parents were heterozygous for 
the ena mutant allele, 25% of the embryos picked were 
expected to be homozygous for the ena mutations, 25% 
for the wild-type ena allele, and 50% heterozygous for 
both the mutant and wild-type alleles. As expected, 
25% of the embryos from the enaGC8/wild-type par­
ents did not express the Ena protein (Figure 3, top 
panel). Half of the embryos from the ena23/wild-type 
parents expressed two sizes of Ena protein, and 25% 
had only the slower-migrating species, identical to the 
wild-type protein. The other 25% of the embryos were 
presumably homozygous ena23 mutant embryos that 
expressed a faster-migrating form consistent with the 
presence of a smaller protein (Figure 3, middle panel). 
Embryos from the ena210/wild-type parents all ex­
pressed a full-length protein (Figure 3, bottom panel).
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ENA 1 {MTEQSIIGARASVMVYDDNQKKWVPSGSSS . GLSKVQIYHHQQNNTFRW 
I . I I . : . I I . II : I I I . . I : I : I . I . : . : : I : I I I I I : . . 1 . 1 1 1 1  
VASP 1 {MS ETVIC S SRATVMLYDDGNKRWL PAGTGPQAF SRVQIYHNPTAN S FRW
ENA 5 0 GRKLQ.DHEWINC SILKGLKYNQATATFHQWRDSKFVYGLNFSSQNDAE 
I I I : 1 I : : I I I I I . I : : I : I 1 I I I ! : . I I I I I I . : t : I II I : I . : I I . 
VASP 51 GRKMQPDQQWINCAIVRGVKYNQATPNFHQWRDARQVWGLNFGSKEDAA
ENA 99 NFARAMMHALEVLSG}RVANNPGGPPTNGNGYEEDMGYRTMTSEDAAILRQ 
. 1 1 : 1  1 1 1 . 1 1
VASP 101 QFAAGMASALEALEG}............................................................
ENA 149 NNSIGGHVTPSAQTPTSQTNQNNIPQSPPTPQGHHRTSSAPPAPQPQQQQ 
VASP .......................................................................................
ENA 199 QQQQAQQMGQPGSHYGPTGNGPTSNGLPQQVNSQIPPAPQQQPQQQQFQQ 
VASP .......................................................................................
ENA 249 QQQQQQYQQMVQAGYAPSQQYQQPHYVLSNSNPNLTVHQYPTQQAQQQPP 
VASP .......................................................................................
ENA 299 QAPQPPLQNGGMYMVGHSHLPSSASANSWYASQQQMLPQAHPQAPQAPT 
VASP .......................................................................................
ENA 349 MPGPGYGGPPVPPPQQQAENPYGQVPMPPPMNPSQQQQPGQVPLNRMSSQ 
I I I! I I I I  I II . . ! : :  . 1 : 1 ..
VASP 116 .........GGPPPPPALPTWSVPNGPSPEEVEQQKRQQPGPSEHIERRVSNA
ENA 399 GGPGGPPAPAPPPPPPSFGGAAGGGPPPPAPPQMFNGAPPPPAMGGGPPP 
I I I . : I I I  . : 1 I I I I I I I I !  : I : I I I I : : . I . . 
VASP 160 GGPPAPPAGGPPPPP.............. GPPPPP......... GPPPPPGL. .PPSG
ENA 449 AP PAP PAMGGG P P PAPGG PGAP P P P P P P PGLGGAPKKEDPQADLMG S LAS
. I : I ■: . : I I I I II I I . I : I . . I---- : I . I II.
VASP 193 VPAAAHGAGGGPPPAPPLPAAQGPGGGGAGAPG....................... LAA
ENA 499 QLQQFKLKKNKVTTSAPENSGSSTSSGGSGNYGTIGRSSNGMASMMDEMA
. : . . I I : I ....... I . I I : . I . . : . : I I I : . I : : I : I I .
VASP 229 AIAGAKLRK. . . VSKQEEASGGPTAPKAES....... GRSGGG..GLMEEMN
ENA 549 KTLARRRAQAEKKDPDPEAEVKKRPWEKSNTLPHKLSGGAGSGSAGSGHE 
M i l l . . :  : . • I . . I I : : : 
VASP 269 AMLARRRKATQVGEKTPKDE............................................SANQ
ENA 599 GANGNSGGAGSNTTNSGGESPRPMRKRFGSASEETILKVNGDGLSLALSN
: . : __ 1 . 1 : ........  I . . . . I : I . I . I .............I • -
VASP 293 EEPEARVPAQSESVRRPWEKNSTTLPRMKSSSSVTTSETQPCTPS.SSDY
ENA 649 GPLDTLKAEIVREMRLEIQKVKNEliDAIKSEFNRR 684 
: I I : : I . I : : I : : 1 : 1 1 1 1 : 1 1 1 : 1 : I : - : I 
VASP 3 4 2  S DL ORVKO EL LEEVKKELQKVKEB11EAFVPELRKRGS P 3 8 0
Figure 1. Ena and VASP have structural domain and sequence 
similarity, and the ena 210 and ena 23 mutations map to these 
regions of similarity. (A) Comparison of the overall structure and 
structural domain organization of Ena and VASP. The conserved 
EVH1 domain (hatched box) and EVH2 domain (checked box) are 
separated by a central domain of variable length, which contains a 
region rich in prolines. (B) Comparison of the deduced amino acid
To explain the embryonic lethality associated with 
ena210 and ena23, we speculated that these mutant Ena 
proteins harbored lesions in critical functional do­
mains. Identification of these mutations could be in­
formative about the function of other Ena/VASP fam­
ily members, because they have a high degree of 
functional conservation with Ena. To analyze the na­
ture of these mutations, the coding regions of ena210 
and ena23 were sequenced after reverse transcription 
PCR of total RNA from Drosophila pupae that were 
heterozygous for the ena mutation being examined. A 
single C T mutation was identified in the EVH1 
domain of ena210 that results in an A97V change (Fig­
ure 1B). Examination of the EVH1 domains from pre­
viously cloned family members demonstrated com­
plete conservation of this alanine in all reported Ena/ 
VASP family members (Gertler et al., 1996). Two 
changes were found in ena23 . First was an A ^ G  
change in the proline rich-domain of Ena changing 
N379F. The second was an A  T mutation that intro­
duced a stop codon 52 amino acids from the C termi­
nus of Ena that deletes the EVH2 domain (Figure 1B) 
and encodes a protein consistent with the smaller 
protein seen in the single-embryo Western blots.
The N379F mutation identified in ena23 involves an 
amino acid that is not conserved in any other Ena/ 
VASP family member (Gertler et al., 1996). However, 
the introduction of the stop codon (K636Stop) deletes 
the conserved EVH2 domain. Consequently, we fo­
cused on this mutation and tested whether the 
K636Stop described above contributed to the lethality 
of ena23 . The K636Stop mutation was generated by 
site-directed mutagenesis in an Ena P element trans- 
poson, and transgenic flies were generated. The UAS/ 
GAL4 binary expression system was used to ubiqui­
tously express wild-type or mutant Ena K636Stop in 
Ena null Drosophila embryos. Two Ena K636Stop trans­
genic lines were tested and rescued from 0 to 8% of the 
expected homozygous ena mutant flies. Both lines ex­
pressed truncated Ena K636Stop protein as assessed 
by Western blots of lysates from transgenic flies in­
duced by GAL4 to express the UAS-ena23 transgene 
(our unpublished observations). This indicates that 
the removal of the EVH2 domain is in part responsible 
for the lethality seen in the ena23 mutant flies. The
Figure 1 (cont). sequences and sequence motifs of Drosophila Ena 
and human VASP. The central regions of both Ena and VASP have 
multiple polyproline motifs. The C-terminal 35 amino acids contain 
a mixed charge cluster containing a charged residue at every fifth 
position (marked in bold). The conserved alanine that is altered in 
ena 210 mutants is in bold and marked with an asterisk. The EVH1 
domains are enclosed in brackets, and the EVH2 domain is under­
lined. The location of the stop codon in ena23 is marked by a plus 
sign. Sequence alignment was generated using the Genetics Com­
puter Group (Madison, WI) BestFit program. Amino acid identity is 
indicated by vertical lines, and similarity is indicated by dots.
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Table 1. Rescue of ena mutant flies with ena and VASP transgenes
Transgene Experiment
Expected no. of ena 
mutant fliesa
Observed no. of rescued 
ena mutant flies Rescue (%)b
Average rescue per 
line (%)
wt1A 1 140 107 76
2 82 63 77 79
3 135 112 83
wt1B 1 118 116 98
2 96 102 106 100
3 131 128 98
wt10A 1 115 93 81
2 87 76 87 87
3 78 72 92
VASP.A 1 116 94 81
2 90 82 91 85
3 123 101 82
VASP.3 1 65 32 49
2 61 18 30 40
VASP.K 1 65 16 25
2 104 25 24 24
3 87 20 23
VASP.C 1 116 33 28
2 117 23 20 24
3 102 24 24
VASP.F 1 118 39 33
2 115 32 27 26
3 92 16 17
a Expected number of ena mutants was calculated as one-half of the observed ena heterozygotes.
b Percent rescue was determined by dividing the observed number of Cy ena homozygotes by the expected number of ena mutants.
identification of lethal mutations in the EVH1 and 
EVH2 domains of Ena is strong evidence that these 
domains are critical for in vivo Ena function and by 
analogy for in vivo functions of the Ena/VASP family 
of proteins.
Drosophila Enabled Binding to Zyxin Is Disrupted 
In ena210
Previous studies with VASP and Mena have demon­
strated that the EVH1 domain is involved in binding 
the focal adhesion-associated protein zyxin (Reinhard 
et al., 1995a; Gertler et al., 1996). Based on these obser­
vations, we speculated that the EVH1 domain from 
Drosophila Ena would also bind zyxin. We examined 
the zyxin binding properties of Ena with a filter bind­
ing assay and found that Ena, like VASP and Mena, 
bound to the zyxin protein (Figure 4A). The zyxin 
protein consists of three highly conserved LIM do­
mains and a proline-rich domain. We expressed full- 
length zyxin and the LIM and proline-rich domains of 
zyxin individually as GST fusion proteins and tested 
in solution-binding assays for binding to Ena or to 
human VASP. As expected, both proteins bound to the 
full-length zyxin protein. Both proteins also bound to 
the proline-rich region of zyxin but not to the LIM 
domains (Figure 4B), consistent with results obtained 
for VASP and Mena (Niebuhr et al., 1997) and indicat­
ing that the ability to bind zyxin is conserved in Dro­
sophila Ena and mediated through the same region of 
zyxin. To investigate whether Ena and zyxin can as­
sociate in vivo, we compared their subcellular distri­
bution in mammalian cells transfected with Ena. Both 
Ena and zyxin are detected at focal adhesion contacts 
and on microfilaments (see Figure 9, 1A  and 1B).
To determine whether the A 97V change affected 
zyxin binding to the Ena EVH1 domain, we examined 
the zyxin binding properties of wild-type and A 97V 
mutant Ena by generating this mutation in the Ena 
cDNA and cloning these cDNAs into the pCite expres­
sion vector. Wild-type or Ena A97V proteins were 
produced using a combined in vitro transcription- 
translation reaction and tested in solution-binding as­
says for their ability to bind GST-zyxin. Although 
equal amounts of the wild-type and mutant proteins 
were expressed, less mutant Ena A 97V protein was 
pulled down by the GST-zyxin fusion protein when 
compared with the wild-type Ena protein (Figure 5C). 
In contrast, both proteins bound equally well to the 
GST Abl SH3 domain, demonstrating that the muta­
tion is specific for an EVH1 domain function and does 
not disrupt the proline-rich central region of Ena (Fig­
ure 5B). This suggests that the mutation does not cause 
an overall disruption of the Ena protein structure. To 
further confirm that the A 97V change in Ena affects
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Figure 2. Colocalization of Ena and VASP proteins to stress fibers and focal contacts in transfected PtK2 cells. PtK2 cells were transiently transfected with 
pCMV / ena (A-C) or pCMV /  ena and pVSV-VASP (D-F) and processed for double-label immunofluorescence microscopy. Ena was detected with rabbit 
polyclonal antibodies (A and D), VASP with a monoclonal mouse anti-VSV antibody (E), and F-actin by fluorescein-labeled phalloidin (B). A merge 
of A and B is shown in C, and a merge of D and E is shown in F. Fluorescent staining was by TRITC for Ena and DTAF for VASP. Ena expressed 
alone is localized either in focal contacts and stress fibers or is also variably found in spot-like structures, which also stain for F-actin (A-C). 
Coexpression of Ena and human VASP results in an identical localization of the two proteins in focal contacts and stress fibers (D-F). Controls show 
no cross-reactivity of the anti-Ena antibodies with VASP. Nuclear fluorescence is nonspecific background because of the secondary antibody.
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enaGC1/enaGC5 1 120 0
2 115 0
ena23/enaGC1 1 120 0
2 117 0
ena210/enaGC1 1 126 0
2 101 0
a The entire progeny was scored for each cross. The expected num­
ber of Ena mutant flies was calculated as one-half the number of the 
balanced, heterozygous siblings.
zyxin binding, we examined the ability of this mutant 
protein to colocalize with zyxin in transfected mam­
malian cells. In contrast to wild-type Ena and zyxin, 
which are clearly present in the focal contacts, the
Figure 3. Analysis of ena mutant alleles. Single-embryo Western 
blot analysis of heterozygous ena mutant stocks. Embryos were 
collected for 2 h and then aged 5 h. Single embryos were picked and 
lysed in sample buffer and Western blotted. For the enaGC8 chro­
mosomal inversion, 25% of the embryos were null for Ena protein 
(top panel, lanes 1, 5, and 9). This blot was stripped and reprobed 
with an anti-fax antibody to demonstrate the presence of embryonic 
proteins in all 12 lanes. The ena 23 allele appears to encode an Ena 
protein with a small truncation, because 25% of the embryos encode 
only a smaller protein (small arrow) of 80 kDa (middle panel, 
lanes 3, 9, and 12), and 50% of the embryos encode both full-length 
Ena (large arrow) and the truncated protein. The ena 210 allele 
appears to encode a full-length protein, because all embryos picked 
express full-length Ena.
Figure 4. Binding of Ena and VASP proteins to zyxin and mapping 
of the binding domain in zyxin. (A) Ena and VASP overlays were 
carried out essentially as previously described (Reinhard et al., 
1995a). Fifty micrograms of total protein from human platelets (lane 
1) and 100 ng of purified porcine platelet zyxin (lane 2) were 
separated by SDS-PAGE and transferred to nitrocellulose. The blot 
was overlaid with Ena purified from baculovirus-infected cells, and 
bound Ena was detected by the anti-Ena antibody followed by 
125I-protein A (left panel). The control (right panel) was treated 
identically, except that the overlay solution contained no Ena pro­
tein. Ena protein bound to an 83-kDa protein present in platelet 
lysates (lane 1), which comigrates with full-length zyxin (lane 2), 
whereas the control panel gave no detectable signal (right panel).
(B) S2 cells were transfected with Ena or VASP, and proteins were 
bound to GST fusion proteins as follows: full-length chicken zyxin 
(lane 1), zyxin proline domain (lane 2), zyxin LIM domains (lane 3) 
(Schmeichel and Beckerle, 1994), and GST alone (lane 4). Retained 
proteins were detected with anti-Ena N-terminal (left panel) or 
anti-VASP (right panel) polyclonal antibodies. Both proteins bound 
to full-length zyxin and to the zyxin proline domain (lanes 1 and 2). 
Neither protein bound to the zyxin LIM domain (lane 3). The faint 
signal seen in lanes 3 and 4 in the anti-VASP blot is due to back­
ground binding between VASP and the GST fusion proteins. Ali­
quots of transfected cell lysates were analyzed for expression of Ena 
or VASP protein (lanes 5). These results are representative of three 
independent experiments.
A97V mutant Ena exhibits diffuse staining and is ab­
sent from the focal contacts (see Figure 9, 2A  and 2B). 
We conclude that EVH1 binding domain function is 
required for Ena's function in Drosophila.
The EVH2 Domain o f Drosophila Enabled Mediates 
Multimerization
Truncation of the EVH2 domain by the mutation 
identified in Ena K636Stop results in embryonic le­
thality, suggesting that this region of Ena may me­
diate a critical function of the Ena protein. Initial 
clues to this function came by the isolation of the 
EVH2 domain of Ena in a yeast two-hybrid screen 
for Drosophila proteins that interact with the C-ter­
minal 243 amino acids of Ena. The C-terminal 243 
amino acids of Ena were fused to the D N A binding 
domain of the yeast transcription factor Gal4 and
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Figure 5. ena 210 mutation disrupts zyxin binding. Full-length 
wild-type Ena (WT) or ena210 (A97V) proteins were prepared using 
an in vitro transcription-translation reaction and bound to GST 
alone (A), GST-AblSH3 (B), or GST-zyxin (C). Retained proteins 
were detected with anti-Ena N-terminal polyclonal antibody. Both 
proteins were expressed equally well (D). As expected, the GST 
negative control did not bind detectably to either protein (A). Both 
proteins bound equally well to the GST-AblSH3 domain (B). The 
wild-type Ena protein bound to the GST-zyxin protein, whereas 
binding to the A97V mutant protein was reduced. (C) These results 
are representative of three independent experiments.
used to screen a third instar larval library whose 
inserts were fused to the activation domain of Gal4. 
The separately expressed domains are unable to 
activate transcription of the reporter genes HIS3 and 
LacZ unless a protein-protein interaction takes 
place (Chien et al., 1991). Clones (20.5 million) were 
screened, 9 of which interacted with Ena as assessed 
by expression of both the HIS and LacZ reporter 
genes. Two of these clones were partial Ena cDNAs 
encoding Ena amino acids 628-684 and 634- 684, 
respectively. The interaction was specific, because a
Figure 6. Interaction of the Ena EVH2 domain with the C- 
terminal 243 amino acids of Ena in the yeast two-hybrid system. 
The first 235 amino acids of Ena (GAL4DB-Ena1-235) and last 243 
amino acids of Ena (GAL4DB-Ena441-684) were fused to the se­
quence encoding the GAL4 DNA-binding domain in the pAS1- 
CYH2 vector. These two constructs were cotransformed with 
GAL4AD-Ena628-684, a clone in which amino acids 628-684 of 
Ena are fused to the sequence encoding the GAL4 activation 
domain and that was isolated in a yeast two-hybrid screen using 
the C terminal 243 amino acids of Ena as bait. Four independent 
colonies from each of the cotransformations were spread on 
medium lacking histidine and analyzed for growth. GAL4DB- 
Ena44
can interact with GAL4AD-Ena6
containing the C-terminal region of the Ena protein
(A, EnaC EnaC), 
whereas GAL4DB-Ena1-235 cannot (C, EnaN EnaC). As a con­
trol, GAL4DB-Ena1-235 and GAL4DB-Ena401-684 were also tested 
for their ability to interact with GAL4AD-SE5, a clone identified 
from the same larval library as GAL4AD-Ena628-684 by its ability 
to interact with GAL4DB-Ena1-235. As expected, GAL4DB-Ena1- 
235 can interact with GAL4AD-SE5 (B, EnaN SE5), whereas 
GAL4DB-Ena401-684 cannot (D, EnaC SE5).
construct with the Ena N-terminal domain fused to 
the D N A binding domain of Gal4 did not interact 
with these same isolated clones (Figure 6). Seven 
additional unique sequences were also identified 
that w ill be described in a later report. We thus 
speculated that the EVH2 domain may be involved 
in mediating multimerization of Ena/V A SP pro­
teins.
To assess the ability of Ena to multimerize, Ena 
expression vectors were generated in which full- 
length Ena was tagged at the C terminus with a 
6-histidine tag for purification on Ni-NTA resin. 
Hemaglutinin or FLA G  epitopes were then added to 
the C terminus of either full-length Ena or Ena
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Figure 7. The EVH2 domain mediates multimerization. (A) S2 cells were transfected with the following expression constructs: no DNA 
(lane 1), Ena-FLAG (lane 2), Ena K636Stop-FLAG (EnaStopFlag; lane 3), Ena-His (lane 4), Ena-FLAG + Ena-His (lane 5), and Ena 
K636Stop-FLAG (EnaStopFlag) + Ena-His (lane 6). Cells were lysed, and extracted proteins were purified on Ni-NTA agarose and 
blotted with anti-FLAG (top panel) or anti-Ena (bottom panel) antibodies. Aliquots of cell lysates representing 2% of the total protein 
used in the purifications were analyzed with the anti-FLAG antibody for expression of the FLAG-tagged proteins, and both the 
Ena-FLAG and EnaK636Stop-FLAG proteins were expressed in the presence of Ena-His (middle panel). However, only full-length 
Ena-FLAG copurified with the Ena-His on the nickel NTA resin (top panel, compare lanes 5 and 6). A small amount of contaminating 
Ena-FLAG was purified with the Nickel-NTA resin (top panel, lane 2). (B) S2 cells were transfected with the following expression 
constructs: no DNA (lane 1), VASP + Ena-Ha (lane 2), and VASP + Ena K636Stop-Ha (EnaStopHa; lane 3). Transfected cell lysates were 
immunoprecipitated with 5 /u,g of anti-Ha antibody. Complexes were subsequently analyzed by Western Blot with an anti-VASP 
antibody (top panel) or anti-Ena antibody (bottom panel). Aliquots of cell lysates representing 2% of the total protein used for the 
immunoprecipitations were analyzed for expression of the VASP protein with an anti-VASP antibody (middle panel). VASP was 
expressed in the presence of Ena-Ha and Ena K636Stop-Ha (middle panel, lanes 2 and 3), but VASP only copurified with full-length 
Ena-Ha in the anti-Ha IPs (compare lanes 2 and 3, top panel). The dark band present in all lanes in the top panel is the heavy-chain 
antibody from the anti-Ha IPs cross-reacting with the secondary antibody of the Western blot (arrow).
K636Stop. The tagged Ena and Ena K636Stop pro­
teins were recognized by commercially available 
mAbs directed against FLAG  (M2) or Ha (12CA5) 
epitopes. S2 cells were transfected with the FLAG- 
tagged Ena or Ena K 636Stop expression vectors in 
the presence or absence of the His-tagged Ena ex­
pression vector. Transfected cell lysates were puri­
fied on Ni-NTA resin, and isolated complexes were 
analyzed by Western blot using the anti-FLAG 
mAb. When the His-tagged Ena w as expressed in 
the presence of the full-length FLAG-tagged Ena, a 
strong FLAG signal was seen, suggesting that the 
two differentially tagged proteins formed a complex 
in cultured cells (Figure 7A, lane 5). However, there 
was no evidence of complex formation between the 
His-tagged Ena and the FLAG-tagged Ena K636Stop 
protein, indicating that this interaction required the 
Ena EVH2 domain (Figure 7A, lane 6).
Ena and the Ena/VA SP fam ily of proteins share 
similarity in the EVH2 domain. To determine 
whether this sequence conservation translated to 
functional conservation, w e looked for complex for­
mation between VASP and Ena or Ena K636Stop. S2 
cells were transfected with VASP and Ha-tagged 
Ena or Ena K636Stop expression vectors. Trans­
fected cell lysates were immunoprecipitated with 5 
/xg of anti-Ha antibody, and complexes were ana­
lyzed by Western blot using an anti-VASP antibody. 
As seen with Ena, VASP associated with full-length 
Ena (Figure 7B, lane 2), whereas no evidence of 
complex formation was detected with Ena 
K636Stop, which lacks the EVH2 domain (Figure 7B, 
lane 3). Taken together, the coprecipitation and 
yeast two-hybrid data suggest that the EVH2 do­
main is necessary and sufficient to mediate Ena 
multimerization with both Ena and VASP. There­
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fore, this EVH2 function appears to be conserved 
within the Ena/V A SP fam ily and may be essential 
for Ena's in vivo effects.
The EVH2 Domain Is Important fo r  Ena's A bility to 
Bind the Abl-SH3 Domain and Zyxin
Because the ability to multimerize may be an impor­
tant property of the Ena protein, we speculated that it 
may be required for other known functions of Ena. 
Studies in other laboratories have indicated that mul- 
timerization of proteins can alter their ligand-binding 
capacity (Oh et al., 1997; Seiffert, 1997). We thus de­
cided to test the effect of removing the Ena EVH2 
domain on its affinity for the Abl-SH3 domains and 
zyxin. S2 cells were transfected with Ena or Ena 
K636Stop expression vectors. Full-length zyxin and 
the Abl SH3 domain were expressed as GST fusion 
proteins and bound in solution to the transfected cell 
lysates, and bound complexes were analyzed by West­
ern blot analysis using the anti-Ena antibody. A l­
though the mutant and wild-type Ena proteins were 
expressed equally well, less of the Ena K636Stop pro­
tein was pulled down by both the Abl SH3 domain 
(Figure 8C, lane 3) and zyxin (Figure 8D, lane 3) when 
compared with the full-length Ena protein (Figure 8, C 
and D, lanes 2). To further confirm that the Ena 
K636Stop change in Ena affects its ability to bind 
zyxin, we examined the ability of this mutant protein 
to colocalize with zyxin in transfected mammalian 
cells. In contrast to wild-type Ena and zyxin, which are 
clearly present in the focal contacts, K636Stop mutant 
Ena exhibits more diffuse staining with reduced stain­
ing in the focal contacts (Figure 9, 3A  and 3B).
D IS C U S S IO N
In this report, we have taken advantage of the Dro­
sophila system to demonstrate in vivo that there is a 
striking degree of functional conservation between 
Drosophila Ena and human VASP, both members of the 
recently described Ena/VASP family of proteins. Spe­
cifically, we have demonstrated that human VASP can 
partially substitute for a loss of Ena in the developing 
Drosophila embryo. This is particularly striking in light 
of the limited sequence identity that these two pro­
teins share, primarily in the EVH1 and EVH2 do­
mains. In addition, two lethal Ena mutations that map 
to the EVH1 and EVH2 domains of Drosophila Ena 
have been described and characterized. Identification 
of functional mutations in the EVH1 and EVH2 do­
mains of Ena are of particular interest because of the 
high degree of similarity in both sequence and func­
tion between different Ena/VASP family members, 
which, by analogy, implicates these protein domains 
as critical functional domains in other Ena/VASP fam­
ily members.
Figure 8. Ena K636Stop is impaired in its ability to bind zyxin and 
the Abl-SH3 domain. S2 cells were transfected with no DNA (lanes 
1), full-length Ena (lanes 2), or Ena K636Stop (lanes 3) expression 
vectors. Transfected cell lysates were incubated with GST-Zyxin (D) 
or Abl SH3 (C) domain fusion proteins or with GST alone as a 
negative control (B). Cells were lysed, and aliquots of the cell lysates 
were compared to confirm that equal amounts of the full-length and 
truncated Ena proteins were expressed (A). Lysates were incubated 
with the GST fusion proteins, and retained proteins were detected 
with anti-Ena N-terminal polyclonal antibody. Little protein bound 
to the GST negative control (B). A decrease in binding of the trun­
cated Ena K636Stop protein was seen with both zyxin and Abl SH3 
when compared with the full-length Ena protein (C and D, compare 
lanes 2 and 3). These results are representative of three independent 
experiments.
One of the shared properties of Ena and VASP that 
may account for the observed rescue of Ena mutant 
flies by expression of human VASP is the ability to 
bind in vitro to the focal adhesion protein zyxin. Pre-
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Figure 9. Comparison of the subcellular distribution of zyxin and wild-type or mutant Ena. Human fibroblasts were transiently transfected 
with pCMV/Ena (1), pCMV/EnaA97V (2), or pCMV/EnaK636Stop (3) and processed for double-label immunofluorescence microscopy. Ena 
staining is shown in A, staining of endogenous zyxin in B. After transfection of wild-type Ena (1A and 1B), colocalization of both Ena and 
zyxin is found in focal contacts, on microfilaments and in spot-like structures. A magnification of the area indicated by the arrow showing 
two "spots" and several focal contacts is seen at the top right (insets in 1A and 1B). In contrast, EnaA97V (2A and 2B) is diffusely distributed 
throughout the cytoplasm and totally absent from focal contacts, which are labeled by the zyxin antibody. EnaK636Stop (3A and 3B) is also 
diffusely distributed in the cytoplasm but shows some residual focal contact staining, although less pronounced than that of the wild-type 
Ena protein. Bar in 1A, 20 /xm (valid for all panels).
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vious studies demonstrated that the focal adhesion- 
associated protein zyxin binds VASP and Mena 
through the EVH1 domain (Reinhard et al., 1995b; 
Gertler et al., 1996). Here we demonstrated that this 
binding is conserved in Ena and is mediated by the 
zyxin proline-rich domain, consistent with recent pep­
tide-mapping and competition studies of the Ena/ 
VASP binding domain in zyxin (Niebuhr et al., 1997). 
This would leave the zyxin LIM domains, which have 
been shown to mediate protein-protein interactions, 
available to link the zyxin-Ena/VASP complexes to 
other cellular proteins (Sadler et al., 1992; Schmeichel 
and Beckerle, 1994; Arber and Caroni, 1996). Binding 
to zyxin may provide a specific mechanism for local­
ization of Ena and VASP to focal adhesions that may 
permit Ena/VASP proteins to direct actin assembly to 
sites of contact between the cell and the extracellular 
environment. Consistent with this is our report that 
Ena, like VASP, is localized to focal adhesions and our 
observation that Ena colocalizes with endogenous 
zyxin when expressed in cultured mammalian cells.
We have also shown that zyxin binding is disrupted 
by the A97V mutation identified in the EVH1 domain 
of Ena in ena210. This alanine is conserved between 
Drosophila Ena and VASP, as well as in murine Ena, 
EVL, and Drosophila AE33 (Haffner et al., 1995; DeMille 
et al., 1996; Gertler et al., 1996; Symons et al., 1996). 
Taken together, these data suggest that this alanine is 
important for the overall structure of the EVH1 do­
main and that this domain is critical for Ena function. 
A  Drosophila protein related to zyxin has been identi­
fied (our unpublished results). It will be interesting to 
determine whether this protein is a ligand for the Ena 
EVH1 domain, and further studies will be necessary to 
determine this. However, because this Drosophila pro­
tein has not yet been purified and antibodies directed 
against it are not available, it is not presently possible 
to test this possibility. It is also possible that Ena may 
bind a different Drosophila protein through this same 
highly conserved, critical binding domain. In fact, in 
addition to zyxin, VASP and Mena have also been 
shown to bind to both vinculin and bacterial Act A 
through the EVH1 domain, bolstering the argument 
that multiple proteins may interact with this domain 
to influence cytoskeletal assembly (Gertler et al., 1996; 
Reinhard et al., 1996). Efforts are currently under w ay 
to definitively identify all the potential binding part­
ners for this critical domain of Drosophila Ena. Thus, 
although it is not yet clear that Ena/VASP proteins 
share the same binding specificity, our in vivo rescue 
data suggest that the EVH1 domains from these pro­
teins recognize an overlapping set of proteins in vivo.
A  second Ena mutation was identified that results in 
truncation of the Ena EVH2 domain. Although several 
potential functions have been proposed for this con­
served protein domain, we provide compelling in 
vitro evidence that it may be involved in multimer
formation. This function of the EVH2 domain is con­
served among family members, because Ena also 
forms multimers with VASP, and this multimerization 
requires the Ena EVH2 domain. Additionally, loss of 
the EVH2 domain reduces Ena's ability to bind to 
zyxin and to the Abl SH3 domain in vitro. Because the 
zyxin binding domain has already been mapped to the 
EVH1 domain (Gertler et al., 1996; Niebuhr et al., 1997) 
and the Abl-SH3 binding domain has been mapped to 
the Ena proline-rich sequences (Gertler et al,  1995), we 
propose that this decrease in zyxin and Abl-SH3 bind­
ing may be due to a loss of ability to multimerize.
It is possible that removal of the Ena EVH2 domain 
disrupts the overall structure of the Ena protein, thus 
resulting in the reduction of zyxin and SH3 binding. 
This seems unlikely, however, in light of several ob­
servations. First, truncated forms of Ena lacking the 
EVH2 domain are expressed stably in both S2 cells 
and in Drosophila and are efficiently phosphorylated 
by the Abl tyrosine kinase (Gertler et al., 1995). Second, 
Gertler et al. (1996) have shown that an isolated EVH1 
domain is able to localize to focal adhesions in cul­
tured cells when injected as a GST fusion protein, 
suggesting that removal of the Mena C terminus does 
not grossly alter the structure of the EVH1 domain 
(Gertler et al., 1996). Because GST domains are re­
ported to form multimers (Reinemer et al., 1991), it is 
possible that GST-mediated multimerization may 
have compensated for the lack of EVH2 domain in the 
GST-EVH1 fusion protein in these experiments 
(Gertler et al., 1996). Thus, we propose that loss of the 
EVH2 domain may reduce binding to Ena ligands 
through a loss of ability to multimerize. This would be 
similar to the effect of multimerization on the ligand- 
binding properties of both vitronectin and syndecan-4 
(Oh et al., 1997; Seiffert, 1997).
Zyxin binding is thought to be a mechanism for 
localizing Ena/VASP proteins to focal adhesions. 
Thus, multimerization of Ena/VASP proteins may be 
necessary for proper subcellular localization of these 
proteins to focal adhesions and the actin cytoskeleton. 
This would be consistent with results demonstrating 
that removal of the C-terminal 100 amino acids of 
VASP, which includes the EVH2 domain, results in an 
absence of VASP in the focal adhesions (Haffner, et al.
1995). Interestingly, our results indicate that both the 
EnaA97V and the EnaK636Stop mutants show a rather 
diffuse intracellular localization and were clearly ab­
sent from focal contacts when expressed in mamma­
lian cells.
Localization of the Ena/VASP family of proteins at 
focal adhesions places them at cellular structures 
where bidirectional signal transduction takes place 
(Machesky, 1997). Thus, it is of particular interest that 
in addition to being cytoskeletal proteins, this family 
of proteins represents docking sites and substrates for 
signal transduction molecules. Several kinases phos-
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phorylate Ena, Mena, and VASP, indicating that mul­
tiple signaling pathways act on these proteins to reg­
ulate cytoskeleton assembly (Halbrugge, et al., 1990; 
Gertler et al., 1996; Comer et al., 1997). A  biological 
function has been demonstrated for the Abl-mediated 
phosphorylation of Drosophila Ena, because mutation 
of the Ena tyrosine phosphorylation sites to phenylal­
anine partially impairs the ability of Ena to restore 
viability to Ena mutant animals (Comer et al., 1997). It 
is interesting to note that this unphosphorylatable 
form of Ena is only partially impaired in function and 
does retain some ability to rescue Ena mutants in light 
of the fact that VASP, a protein that is not a substrate 
of Abl, can also partially rescue a loss of ena function 
in Drosophila. Perhaps phosphorylation by Abl is only 
most important for fine tuning of Ena function. Thus, 
VASP, like the unphosphorylatable form of Ena, 
would substitute for Ena's basic functions, such as 
profilin and zyxin binding, ability to multimerize, and 
proper subcellular localization. However, it would be 
unresponsive to signals from Abl that more subtly 
regulate its activity and would thus not able to rescue 
as well as a wild-type Ena protein.
Previous studies have demonstrated that two mem­
bers of the growing Ena/VASP family of proteins, 
VASP and Mena, are linked to cytoskeletal assembly 
(Machesky, 1997). We now demonstrate the functional 
conservation of these proteins to Drosophila Ena by the 
ability of human VASP to partially compensate for a 
loss of Drosophila Ena in vivo and the identification of 
lethal Ena mutations in the most conserved domains 
of the Ena/VASP family. Despite their striking simi­
larities, it is clear that Ena/VASP proteins regulate 
multiple distinct cellular processes and respond to 
different signal transduction pathways because VASP 
is involved in regulation of platelet adhesion and ag­
gregation, and Ena and Mena are associated with neu­
ral development and function. We propose that these 
proteins could provide a bridge between signal trans­
duction and the cytoskeleton. Further study of this 
new family of proteins promises to provide new in­
sights into the regulation of cytoskeleton dynamics 
during development.
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